What does cannabis research say about fibromyalgia? We've analyzed 7 peer-reviewed studies to give you an honest, evidence-based overview.
Multiple high-quality studies support cannabis for this condition.
Study found evidence of effectiveness
No significant effect found
More research needed
* Outcomes are based on our curated selection of research reviews. Individual study quality varies.
About This Research Summary: The information below aggregates findings from multiple peer-reviewed studies on cannabis and fibromyalgia. This is for educational purposes only.
Research summaries are our interpretations of published studies. Individual responses to cannabis vary significantly. These findings do not guarantee similar results for any individual.
Study data sourced from PubMed®. Not evaluated by the FDA. See our Research Content Policy.
Fibromyalgia is a chronic condition affecting 4 million US adults, characterized by widespread musculoskeletal pain, fatigue, sleep problems, and cognitive difficulties often called "fibro fog." The pain of fibromyalgia is distinct—it's amplified throughout the body and often accompanied by heightened sensitivity to touch, temperature, and other stimuli. Despite being a recognized medical condition, fibromyalgia remains poorly understood and often difficult to treat. There's no definitive diagnostic test, and symptoms overlap with many other conditions. Patients frequently endure years of being told their pain isn't real before receiving a diagnosis. Standard treatments include pain medications, antidepressants (which can help pain processing), anti-seizure drugs like pregabalin (Lyrica), and exercise/physical therapy. However, many patients find these approaches provide incomplete relief, leading to interest in alternatives like medical cannabis.
Fibromyalgia may involve dysfunction of the endocannabinoid system—a theory called "Clinical Endocannabinoid Deficiency." This could explain why cannabis helps many fibromyalgia patients when other treatments have failed. THC may reduce pain perception through CB1 receptors in the brain and spinal cord. Since fibromyalgia involves amplified pain processing centrally (not just at pain sites), this central mechanism of action makes sense. CBD's anti-inflammatory properties and potential effects on serotonin signaling may help with the mood and fatigue aspects of fibromyalgia. The combination of THC and CBD may address multiple symptoms simultaneously. Beyond pain, many fibromyalgia patients report improvements in sleep quality, which is crucial since poor sleep worsens fibromyalgia symptoms. Breaking the pain-poor sleep-more pain cycle is a key treatment goal.
Note: This information summarizes research findings and is not medical advice. Consult a healthcare provider before using cannabis for any medical condition.
Based on our analysis of peer-reviewed studies on cannabis and fibromyalgia:
Based on research, these cannabinoids show the most promise for fibromyalgia:
Research suggests THC is the primary driver of pain relief in fibromyalgia. A 2019 study found THC-dominant varieties outperformed CBD-dominant ones. Start low due to fibromyalgia patients' often high sensitivity.
Combination products may help address the multiple symptoms of fibromyalgia—pain, sleep, mood—while CBD potentially moderates THC side effects. Many patients prefer balanced products.
CBD alone may help with anxiety, sleep, and inflammation components of fibromyalgia, but research suggests it's less effective than THC for the core pain symptoms. Consider for daytime use or THC-sensitive patients.
Individual responses vary. Work with a healthcare provider to determine the best approach for your situation.
Fibromyalgia patients often have heightened sensitivity to medications, including cannabis. Starting doses should be lower than typical—1-2.5mg THC initially, increasing by 1-2.5mg every few days. The 2019 Israeli study used an average of 670mg of cannabis flower daily (approximately 26mg THC) after 6 months, but patients titrated to this slowly from much lower starting doses. Many fibromyalgia patients use cannabis multiple times daily: a CBD-dominant or lower-THC product during the day for pain without impairment, and a THC-dominant product at night for pain and sleep. Track symptoms carefully—fibromyalgia symptoms fluctuate, and it can be hard to know what's working. Use a symptom diary for at least 4-8 weeks when starting or adjusting cannabis.
Dosing information is based on clinical research and is for educational purposes only. Optimal dosing varies by individual, product formulation, and administration method. Always start with the lowest effective dose and titrate slowly under medical supervision.
When considering cannabis for fibromyalgia, be aware of these potential concerns:
Discuss these considerations with your healthcare provider before starting cannabis therapy.
A 2019 study of 367 fibromyalgia patients found 81% experienced significant improvement after 6 months of medical cannabis. Average pain scores dropped from 9.0 to 5.0 on a 10-point scale (Sagy et al., Journal of Clinical Medicine).
Source: Sagy et al., Journal of Clinical Medicine, 2019 (PMID: 31195754)
A 2019 study comparing cannabis varieties found THC-dominant products more effective for fibromyalgia pain than CBD-dominant or balanced varieties. Most patients needed THC for adequate pain relief, though CBD may help other symptoms.
Source: van de Donk et al., Pain, 2019 (PMID: 30585986)
A 2020 randomized controlled trial found THC-rich cannabis oil significantly improved fibromyalgia pain, fatigue, and ability to work compared to placebo over 8 weeks, with no serious side effects (Chaves et al., Pain Medicine).
Source: Chaves et al., Pain Medicine, 2020 (PMID: 33118602)
Studies suggest many patients can reduce other medications. 73% of patients in one study reduced or stopped other pain medications after starting cannabis. However, always work with your doctor when adjusting medications.
Source: Sagy et al., Journal of Clinical Medicine, 2019 (PMID: 31195754)
Common questions about cannabis for fibromyalgia:
These 2024 clinical practice guidelines, based on 70 studies, conclude that cannabis-based medicines show "moderate benefit" for chronic pain and also help related conditions like sleep problems and anxiety. The guidelines provide practical dosing and titration recommendations for clinicians.
In this 8-week controlled trial, women with fibromyalgia taking THC-rich cannabis oil showed significantly improved quality of life scores compared to placebo. Pain, fatigue, ability to work, and overall well-being all improved—with no intolerable side effects.
81.1% of fibromyalgia patients reported significant improvement after 6 months of medical cannabis treatment, with 73% achieving at least moderate improvement in pain.
This Dutch trial compared four cannabis varieties in fibromyalgia patients and found unexpected results: while balanced THC/CBD produced the most pain relief, adding CBD to THC actually reduced THC's pain-relieving effects. THC-containing varieties improved pressure pain tolerance, but effects were modest overall.
This rigorous meta-analysis of 104 studies found cannabis provides modest pain relief—about 1 in 24 patients benefit—but with a high side effect burden: 1 in 6 experience harm. The authors concluded it "seems unlikely that cannabinoids are highly effective medicines" for chronic pain.
There is no convincing, unbiased, high quality evidence suggesting that nabilone is of value in treating people with fibromyalgia. The tolerability of nabilone was low in people with fibromyalgia.
Currently, there is insufficient evidence for recommendation for any cannabinoid preparations for symptom management in patients with chronic pain associated with rheumatic diseases.
Our reviews are just a starting point. Browse thousands more studies on PubMed for fibromyalgia.
Fibromyalgia is explicitly listed as a qualifying condition in many states. In others, it may qualify under chronic pain or intractable pain provisions. Medical documentation of diagnosis and failed treatments strengthens applications.
Research Summary Disclaimer
This content represents our interpretation of published scientific research for educational purposes. It should not be used to make treatment decisions without consulting a qualified healthcare provider. Individual results may vary from study findings.
FDA Notice
These statements have not been evaluated by the FDA. Cannabis is not intended to diagnose, treat, cure, or prevent any disease. The FDA has not approved cannabis for any medical condition except specific prescription medications.
Copyright & Fair Use
Research summaries are provided under fair use (17 U.S.C. § 107) for educational purposes. We provide brief summaries with attribution, not full reproductions. All studies remain the intellectual property of their respective authors and publishers.
For complete information, see our Terms of Use and Research Content Policy.
